4.6 Article

Differential TRAF3 Utilization by a Variant Human CD40 Receptor with Enhanced Signaling

Journal

JOURNAL OF IMMUNOLOGY
Volume 185, Issue 11, Pages 6555-6562

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1000135

Keywords

-

Categories

Funding

  1. American Heart Association [0815735G]
  2. National Institutes of Health [AI28847, AI49993, CA099997]
  3. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Health, Services Research and Development [383]

Ask authors/readers for more resources

CD40 is required for T cell-dependent humoral immunity, but it can also contribute to the pathogenesis of autoimmunity and B cell malignancy. The TNFR-associated factor (TRAF) 2 and TRAF6 adaptor proteins are positive regulators of CD40 signaling required to activate downstream kinase cascades and transcription factors. In contrast, TRAF3 can serve as a negative regulator of CD40 signaling, and CD40 signals are amplified in TRAF3(-/-) B cells. We previously reported a gain-of-function polymorphism of the human CD40 receptor, hCD40-P227A, which signals in an amplified manner to B lymphocytes. In this study, we show that hCD40-P227A binds more TRAF3 and TRAF5, as well as certain associated proteins, than wild-type-CD40. Studies in TRAF-deficient B cell lines revealed that hCD40-P227A uses TRAF3 as a positive rather than negative regulator. Although located outside of any known TRAF binding sites, the P227A polymorphism can alter TRAF binding and dramatically changes the role played by TRAF3 in CD40 signaling. The Journal of Immunology, 2010, 185: 6555-6562.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available